Type 1 diabetes in both humans and nonobese diabetic (NOD) mice is the result of a complex T-cell--mediated autoimmune process against the pancreatic β-cells. Putative poorly defined environmental triggers conspire with a constellation of genetic elements scattered throughout the genome to elicit a multifactorial autoimmune response that involves virtually every cell type of the immune system. Genome-wide association studies in humans and mice have identified at least 15 different chromosomal regions harboring candidate type 1 diabetes--associated gene loci, in addition to the HLA and H-2 complexes on human and mouse chromosomes 6 and 17, respectively ([@B1][@B2][@B3]--[@B4]).

The ∼45-cM insulin-dependent diabetes 9 (*Idd9*) region on mouse chromosome 4 has a major effect on type 1 diabetes development ([@B5]). NOD mice congenic for the *Idd9* region of C57BL/10 (B10) mice are highly resistant to type 1 diabetes ([@B5]). However, the underlying mechanisms remain unclear. Initial work correlated protection from type 1 diabetes with recruitment of antidiabetogenic CD30/interleukin (IL)-4--expressing cell types into pancreatic islets ([@B5]). Subsequent studies, however, suggested that alternative mechanisms might be at play. For example, using NOD and NOD.B10 *Idd9* mice expressing an insulin promoter-driven influenza hemagglutinin transgene, Martinez et al. found that the B10 *Idd9* region affords tolerance to hemagglutinin-specific CD8^+^ T-cells through a mechanism that does not inhibit their activation in the pancreatic lymph nodes ([@B6]). Another study suggested that *Idd9* controls the recruitment of autoreactive CD4^+^ T-cells to the pancreas ([@B7]). A third study, using NOD mice congenic for the *Idd9/11* region, which partially overlaps B10 *Idd9*, of nonobese resistant mice (8) supported the CD4^+^ T-cell intrinsic effect(s) of B10 *Idd9* reported by Waldner et al. ([@B7]). Additional investigations of congenic NOD mice carrying chromosome 4 fragments around the *Idd9.1* region of different lengths and donor strains reported effects of *Idd9* on invariant natural killer T (iNKT) cell ([@B9]), B-cell ([@B10],[@B11]), or dendritic cell (DC) biology ([@B12]), and even on susceptibility of β-cells to cell death ([@B13]). This rather extensive assortment of mechanisms seemingly unrelated to one another clearly indicates that the effects of *Idd9* on type 1 diabetes are complex and suggest that the phenotypes are probably determined by more than one gene within the *Idd9* region. In fact, it has been established from congenic strain mapping that the B10 *Idd9* region contains at least three type 1 diabetes--associated genes: *Idd9.1*, *Idd9.2*, and *Idd9.3* ([@B5]). A congenic strain having the *Idd9.2* + *Idd9.3* protective subregions (R11) was more susceptible to type 1 diabetes than the strain having all three congenic subregions (R28). However, the R11 strain was more protected from type 1 diabetes than the R35 strain that has a type 1 diabetes--protective B10-derived allele at only *Idd9.3*.

This study was initiated to dissect mechanisms underlying the type 1 diabetes resistance afforded by B10 *Idd9* loci. We used a reductionist experimental approach ([@B14]) that involves comparing the fate and diabetogenicity of a type 1 diabetes--relevant autoreactive CD8^+^ T-cell population in B10 *Idd9*--congenic versus noncongenic, T-cell receptor (TCR)--transgenic NOD mice. Our data show that the B10-derived *Idd9.1* subregion has a powerful suppressive effect on the diabetogenic activity of a prevalent monospecific CD8^+^ T-cell population without impairing its developmental biology or intrinsic diabetogenic potential. We find that this antidiabetogenic effect is mediated by endogenous, nontransgenic T-cells but not B-cells, and show that it is associated with enhanced regulatory activity of CD4^+^CD25^+^ regulatory T-cells not only in TCR-transgenic, but also nontransgenic, NOD.B10 *Idd9.1* mice.

RESEARCH DESIGN AND METHODS
===========================

Mice.
-----

8.3-NOD and 8.3-NOD.*Rag2*^−/−^ mice have been described ([@B15]). NOD.B10 *Idd9R28* (line 1104)--, NOD.B10 *Idd9R11* (line 1105)--, and NOD.B10 *Idd9.3* (line 1106)--congenic mice were developed as described previously ([@B5]). Development of the NOD.B10 *Idd9.1* (line 1565) and NOD.B10 *Idd9.2* (line 1566) strains and the fine-mapping of *Idd9.1* and *Idd9.2* will be the subjects of future reports. 8.3-NOD.B10 *Idd9R28*, 8.3-NOD.B10 *Idd9R11*, 8.3-NOD.B10 *Idd9.1*, 8.3-NOD.B10 *Idd9.2*, and 8.3-NOD.B10 *Idd9.3* mice were established by crossing 8.3-NOD mice with NOD.B10 *Idd9R28* (line 1104), NOD.B10 *Idd9R11* (line 1105), NOD.B10 *Idd9.1* (line 1565), NOD.B10 *Idd9.2* (line 1566), and NOD.B10 *Idd9.3* (line 1106) mice, respectively. The line number associated with each strain refers to the unique line designation for strains bred at Taconic (Germantown, NY). Lines 1565, 1566, and 1106 are available from Taconic through the Emerging Models Program. Lines 1104 and 1105 are no longer extant. [Figure 1](#F1){ref-type="fig"}*A* shows a map of the congenic strains used in this study in comparison to *Idd9*-congenic strains described by others ([@B9],[@B16],[@B17]). Lines 1565, 1566, and 1106 contain the B10 *Idd9.1*, *Idd9.2*, and *Idd9.3* regions alone, respectively. The markers that define the boundaries of the lines described here are given in supplementary Table 1 (available in an online appendix at <http://diabetes.diabetesjournals.org/content/early/2009/10/14/db09-0648/suppl/DC1>), along with the primer sequences of novel markers developed for this study. supplementary Fig. 1 lists the single nucleotide polymorphisms (SNPs) distinguishing B10, B6, and NOD in the *Idd9.1* region defined by line 1565. All genes containing polymorphisms are noted. Also noted are the regions of overlap of the B10 *Idd9* congenic line with R201 of Ueno et al. ([@B9]) and the two Brodnicki et al. ([@B16],[@B17]) B6 *Idd9/Idd11*--congenic lines defining the smallest *Idd11* interval published to date. Information on the congenic strains is also available at <http://www.t1dbase.org/page/DrawStrains> (select the strain of interest). Note that the B10 *Idd9* fragment in line 1565 overlaps the distal 30% of the B10 *Idd9.1* fragment carried by the R201 strain from Ueno et al., and that Brodnicki et al.\'s *Idd11*-congenic strains were produced using B6 donor mice. The 8.3-NOD.*Ig*μ^−/−^, 8.3-NOD.B10 *Idd9.1/Ig*μ^−/−^, and 8.3-NOD.B10 *Idd9.1/Rag2*^−/−^ mice were established by crossing 8.3-NOD and 8.3-NOD.B10 *Idd9.1* with NOD.*Ig*μ^−/−^ and NOD.*Rag2*^−/−^ mice, respectively, followed by backcrossing 8.3-TCR^+^, mutant heterozygous F1 mice to 8.3-NOD.B10 *Idd9.1* mice and intercrossing 8.3-TCR^+^, mutant heterozygous B10 *Idd9.1* homozygous littermates. All mice were housed in specific pathogen-free conditions.

![Antidiabetogenic effects of different B10 *Idd9* intervals on 8.3-CD8^+^ T-cell--enhanced type 1 diabetes. *A*: Chromosome 4, B10 *Idd9*--congenic NOD lines used in this and other studies ([@B9],[@B16]). *B*: Incidence of diabetes in female 8.3-NOD (*n* = 38), 8.3-NOD.B10 *Idd9R28* (*n* = 22), and 8.3-NOD.B10 *Idd9R11* (*n* = 31) mice. *C*: Incidence of diabetes in NOD (*n* = 67) compared with NOD.B10 *Idd9.1* (*n* = 58), NOD.B10 *Idd9.2* (*n* = 57), and NOD.B10 *Idd9.3* (*n* = 67) female mice. *D*: Incidence of diabetes in female 8.3-NOD (*n* = 38), 8.3-NOD.B10 *Idd9.1* (*n* = 100), 8.3-NOD.B10 *Idd9.2* (*n* = 94), and 8.3-NOD.B10 *Idd9.3* (*n* = 85) mice. The Kaplan-Meier survival curves were compared with log-rank test.](zdb0011059570001){#F1}

Peptides and antibodies.
------------------------

Peptides (NRP-A7 and TUM) were purchased from Mimotopes (Clayton, Victoria, Australia). All monoclonal antibodies (mAbs) were purchased from PharMingen (San Diego, CA), unless indicated otherwise. Anti-mouse glucocorticoid-induced tumor necrosis factor receptor (GITR), anti-mouse/rat FoxP3, and anti--folic receptor 4 (FR4) were from eBiosciences (San Diego, CA). Streptavidin-peridinin-chlorophyll-protein complex was from Becton Dickinson (San Jose, CA).

Preparation of DCs.
-------------------

Mesenteric lymph node (MLN) and pancreatic lymph node (PLN) DCs were purified from collagenase-digested MLNs and PLNs using anti-CD11c mAb-coated magnetic beads (Miltenyi Biotec). Purified DCs were pulsed with NRP-A7 or TUM peptides (1 μmol/l) for 1 h at 37°C and then used in proliferation and cytokine secretion assays using 8.3-CD8^+^ T-cells as responders.

Diabetes and insulitis.
-----------------------

Diabetes was monitored by measuring urine glucose with Diastix (Bayer, ON, Canada); animals were considered diabetic after two readings ≥3+. Differences between diabetes survival curves were compared with the Kaplan-Meier log-rank test using Prism software (Graphpad). Insulitis scores were measured on 14 hematoxylin-eosin--stained pancreas sections 150 μm apart, using the following criteria: 0, intact islet; 1, peri-insulitis; 2, up to 25% of the islet infiltrated; 3, 25--50% infiltration; 4, \>50% infiltration.

Proliferation and cytokine secretion assays.
--------------------------------------------

Splenic CD8^+^ T-cells (2 × 10^4^/well) were incubated with NRP-A7/TUM peptide-pulsed (0.0001--1 μmol/l) antigen-presenting cells (APCs; 10^5^ irradiated splenocytes/well) for 2 or 3 days (for cytokine and proliferation assays, respectively) at 37°C in 5% CO~2~. Cytokines in the supernatants were measured by enzyme-linked immunosorbent assay. The 3-day cultures were pulsed with 1 μCi \[^3^H\] thymidine during the last 18 h and harvested. The regulatory activity of CD4^+^CD25^+^ T-cells was measured by adding 0.125--1 × 10^4^ CD4^+^CD25^+^ T-cells preactivated with anti-CD3 mAb and recombinant (r)IL-2 to CD8^+^ cell--APC cocultures for 48 h (interferon γ \[IFN-γ\] content measurements) or 72 h (proliferative activity, assessed by \[^3^H\] incorporation during the last 18 h of culture).

Cytotoxic T-lymphocyte differentiation and ^51^Cr release assays.
-----------------------------------------------------------------

Splenic CD8^+^ T-cells purified from 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice using anti-CD8--coated microbeads (Miltenyi Biotec) (2 × 10^4^ cells/well) were stimulated with NRP-A7--pulsed irradiated NOD splenocytes (10^5^ cells/well) for 3 days and expanded in 0.5 units/ml of rIL-2 (Takeda, Osaka, Japan) for 7--10 days. Cytolytic activity of cytotoxic T-lymphocytes (CTLs) was measured using NRP-A7-- or TUM-pulsed (1 μmol/l) RMA-SK^d^ cells.

T-cell transfers.
-----------------

Splenic CD8^+^ T-cells were purified using iMAG CD8 beads (BD Bioscience) following the manufacturer\'s protocols, labeled with carboxyfluorescein succinimidyl ester (CFSE; 2.5 μmol/l), and injected intravenously (10^7^ CD8^+^ T-cells) into 9- to 11-week-old hosts (NOD or NOD.B10 *Idd9.1*). Hosts were killed 6 days later and their PLNs and MLNs examined for presence of CD8^+^ CFSE^+^ cells. To purify CD4^+^CD25^+^ cells, lymph node and/or splenic cells were enriched for CD4^+^ cells, incubated with anti--CD25-phycoerythrin (PE), and separated using anti-PE mAb-coated beads (Miltenyi Biotec). The purity was \>85% for CD4^+^CD25^+^ cells. The mice were injected intravenously with 2 × 10^5^ cells and monitored for diabetes for 15 weeks.

Statistical analyses.
---------------------

Data were compared using log-rank, Mann-Whitney *U*, or two-way ANOVA tests.

RESULTS
=======

The B10 *Idd9* region suppresses CD8^+^ T-cell--induced diabetes predominantly via *Idd9.1*.
--------------------------------------------------------------------------------------------

To determine whether the B10-derived *Idd9* region that protects from spontaneous type 1 diabetes can also protect from disease accelerated by the presence of a diabetogenic TCR, we introgressed two copies of the B10 *Idd9.1-9.3* and *Idd9.2-Idd9.3* intervals ([Fig. 1](#F1){ref-type="fig"}*A*) into transgenic NOD mice expressing a diabetogenic T-cell receptor, 8.3 ([@B15]). This TCR is representative of a large fraction of islet-associated CD8^+^ T-cells in NOD mice that use highly homologous TCRα chains ([@B15],[@B18],[@B19]) and recognize the mimotopes NRP-A7 and NRP-V7 in the context of the major histocompatibility complex (MHC) molecule H-2K^d^ ([@B20]). These T-cells are already a significant component of the earliest NOD islet CD8^+^ infiltrates ([@B19][@B20]--[@B21]), are pathogenic ([@B15],[@B18]), target a peptide from islet-specific glucose 6 phosphatase catalytic subunit--related protein (IGRP~206--214~, similar to NRP-A7) ([@B22]), and are unusually frequent in the periphery (\>1/200 CD8^+^ T-cells) ([@B23]).

8.3-NOD.B10 *Idd9R28* mice, carrying the complete B10 *Idd9* interval that affords \>95% protection from spontaneous type 1 diabetes ([@B5]), displayed a significantly reduced frequency of diabetes compared with their noncongenic 8.3-NOD counterparts (∼40 vs. 80%) ([Fig. 1](#F1){ref-type="fig"}*B*). The shorter B10 *Idd9.2-Idd9.3* (*Idd9R11*) interval, which provides 60% protection from spontaneous type 1 diabetes ([@B5]), was also antidiabetogenic, but to a much lesser extent ([Fig. 1](#F1){ref-type="fig"}*B*). To ascertain whether the higher antidiabetogenic effect of *Idd9* was due to additive/synergistic effects of loci contained in different subregions, we developed 8.3-NOD mice congenic for each of the individual *Idd9* intervals (*Idd9.1*, *Idd9.2*, and *Idd9.3*); each of the individual *Idd9* congenic regions affords non--TCR-transgenic NOD mice protection from spontaneous type 1 diabetes as shown in [Fig. 1](#F1){ref-type="fig"}*C*. The fine-mapping of the *Idd9.1* and *Idd9.2* regions is in progress and will be the subject of separate reports (D.B.R. et al. and Hamilton-Williams et al., manuscripts in preparation). The *Idd9.3* region is 1.2 Mb with only 15 genes, including the prime candidate *Tnfrsf9*, which encodes 4--1bb (also known as CD137) ([@B24][@B25]--[@B26]). As shown in [Fig. 1](#F1){ref-type="fig"}*D*, the incidence of diabetes in 8.3-NOD.B10 *Idd9.1* mice was virtually identical to that seen in 8.3-NOD.B10 *Idd9R28* mice, suggesting a minor contribution of the B10 *Idd9.2* and *Idd9.3* alleles on 8.3-CD8^+^ T-cell--enhanced type 1 diabetes. In agreement with these observations, the diabetes survival curves corresponding to 8.3-NOD.B10 *Idd9.2* and 8.3-NOD.B10 *Idd9.3* mice were remarkably similar to those seen in 8.3-NOD.B10 *Idd9R11* mice. This is in contrast to what occurs in nontransgenic NOD mice, where *Idd9.2* and *Idd9.3* augment the antidiabetogenic effects of each other and of *Idd9.1* ([@B5]). Because the *Idd9.1* interval is as protective in 8.3-NOD mice as it is in non--TCR-transgenic NOD mice ([@B5]), these data suggest that expression of the diabetogenic TCR overwhelms the antidiabetogenic properties of *Idd9.2* and *Idd9.3*, but not the effects of *Idd9.1*.

The B10 *Idd9.1* allele suppresses 8.3-CD8^+^ T-cell--enhanced diabetes and insulitis without compromising 8.3-CD8^+^ T-cell development or function.
-----------------------------------------------------------------------------------------------------------------------------------------------------

Because the antidiabetogenic effect of the B10 *Idd9.1* region in 8.3-NOD.B10 *Idd9.1* mice was associated with slower progression of insulitis ([Fig. 2](#F2){ref-type="fig"}*A*), we asked whether this region\'s antidiabetogenic activity was mediated by effects on the developmental biology of 8.3-CD8^+^ T-cells. Cytofluorometric studies indicated that the thymi and spleens of both types of mice contained similar absolute and relative numbers of double-positive CD4^+^CD8^+^ thymocytes and/or single-positive CD4^+^ or CD8^+^ T-cells, respectively ([Fig. 2](#F2){ref-type="fig"}*B* and data not shown). In addition, the transgenic CD8^+^ T-cells of both types of mice expressed comparable levels of the transgenic Vβ8.1^+^ TCR and CD8 ([Fig. 2](#F2){ref-type="fig"}*C*), and bound NRP-V7/K^d^ and IGRP~206--214~/K^d^ tetramers (recognized with high and intermediate avidity, respectively) with similar frequency ([Fig. 2](#F2){ref-type="fig"}*D*) and mean fluorescence intensity ([Fig. 2](#F2){ref-type="fig"}*E*).

![Effects of B10 *Idd9.1* on insulitis and 8.3-CD8^+^ T-cell development. *A*: Insulitis scores of 8.3-NOD (*n* = 6) and 8.3-NOD.B10 *Idd9.1* (*n* = 5) at 10 weeks of age. *B*: Flow cytometry profiles of thymocytes (*left*) and splenocytes (*right*) in 8.3-NOD (*n* = 7) and 8.3-NOD.B10 *Idd9.1* (*n* = 6) mice. Values correspond to the means ± standard errors. *C*: Representative anti-CD8 mAb/IGRP~206--214~/K^d^ and anti-CD8 mAb/NRP-V7/K^d^ tetramer staining profiles of PLN cells. *D*: Percentages of thymic, splenic MLN, and PLN CD8^+^ T-cells binding IGRP~206--214~/K^d^ and NRP-V7/K^d^ tetramers. Data (means ± SE) correspond to four mice per strain. *E*: Representative TUM/K^d^ (negative control), IGRP~206--214~/K^d^ (intermediate avidity), and NRP-V7/K^d^ (high avidity) tetramer staining profiles of splenic T-cells from 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice.](zdb0011059570002){#F2}

Functional in vitro assays revealed that the splenic CD8^+^ T-cells of both types of mice proliferated equally well and secreted similar levels of IFN-γ and IL-2 in response to NRP-A7 peptide stimulation over a range of concentrations ([Fig. 3](#F3){ref-type="fig"}*A*). Likewise, in vitro--differentiated 8.3-CD8^+^ T-cells from both strains killed peptide-pulsed target cells with similar efficiency ([Fig. 3](#F3){ref-type="fig"}*B*).

![Effects of B10 *Idd9.1* on the function of naive 8.3-CD8^+^ T-cells. *A*: Proliferation of, and cytokine (IFN-γ and IL-2) production by, CD8^+^ splenocytes purified from 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice in response to NRP-A7 peptide--pulsed irradiated NOD splenocytes. Data are representative of two separate experiments. *B*: CTL differentiation potential and cytolytic activity of in vitro--differentiated 8.3-CTLs from 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice. Naive 8.3-CD8^+^ T-cells (*n* = 3 for each strain) were stimulated with NRP-A7 (1 μmol/l)--pulsed APCs for 3 days and cultured in the presence of rhIL-2 for 4 additional days. Cytotoxicity assays were performed using NRP-A7-- and TUM-pulsed (1 μmol/l) RMA-SK^d^ cells as targets, at different effector/target ratios. Background responses against TUM-pulsed targets were subtracted. *C* and *D*: CFSE-labeled 8.3-CD8^+^ T-cells were injected into 9- to 11-week-old NOD (*n* = 9; five 8.3-NOD donors and four 8.3-NOD.B10 *Idd9.1* donors) and NOD.B10 *Idd9.1* (*n* = 9; six 8.3-NOD donors and three 8.3-NOD.B10 *Idd9.1* donors) hosts and analyzed for dividing (CFSE^low^) CD8^+^ T-cells in pancreatic (PLN) and mesenteric (MLN) lymph nodes 6 days later. *C*: Representative flow cytometry profiles. *D*: Average quantitative data. *E*: Percentages and total numbers of 8.3-CD8^+^ T-cells in the PLNs and MLNs of NOD and NOD.B10 *Idd9.1* hosts (the histogram legend is the same as in *D*). *F*: Proliferation and secretion of IFN-γ by naive 8.3-CD8^+^ T-cells in response to NRP-A7--pulsed DCs isolated from the PLNs or MLNs of NOD and NOD.B10 *Idd9.1* mice. Bars in *A*, *B*, *D*, *E*, and *F* correspond to the standard errors of the means. *P* values were calculated with Mann-Whitney *U* test.](zdb0011059570003){#F3}

Similar results were obtained in vivo. CFSE-labeled 8.3-CD8^+^ T-cells from 8.3-NOD.B10 *Idd9.1* mice proliferated in the pancreatic (but not mesenteric) lymph nodes (PLNs and MLNs, respectively) of wild-type NOD hosts as efficiently as those derived from 8.3-NOD donors ([Fig. 3](#F3){ref-type="fig"}*C*).

Taken together, these observations indicated that the B10 *Idd9.1* allele does not impair the development or function of IGRP~206--214~-reactive CD8^+^ T-cells.

CD8^+^ T-cell--extrinsic inhibition of 8.3-CD8^+^ T-cell activation by B10 *Idd9.1* in vivo.
--------------------------------------------------------------------------------------------

Whereas CFSE-labeled 8.3-CD8^+^ T-cells proliferated equally well in vivo regardless of the *Idd9.1* genotype of the donor mice, CFSE-labeled 8.3-CD8^+^ T-cells from both 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice proliferated significantly less in the PLNs of NOD.B10 *Idd9.1* hosts than in the PLNs of NOD hosts ([Fig. 3](#F3){ref-type="fig"}*C* and *D*), without any obvious effects on the relative or absolute numbers of recruited/retained 8.3-CD8^+^ T-cells ([Fig. 3](#F3){ref-type="fig"}*E*). This suggested that B10 *Idd9.1* somehow impairs the cross-priming of 8.3-CD8^+^ T-cells by endogenous autoantigen-loaded dendritic cells. This was not due to interstrain differences in autoantigen loading of DCs in vivo but rather to impaired PLN DC function because whereas ex vivo, NRP-A7--pulsed DCs purified from the MLNs of NOD and NOD.B10 *Idd9.1* mice could stimulate naive 8.3-CD8^+^ T-cells with similar efficiency, NRP-A7--pulsed DCs purified from the PLNs of NOD.B10 *Idd9.1* mice could not do so as efficiently as NRP-A7--pulsed DCs purified from the PLNs of NOD mice ([Fig. 3](#F3){ref-type="fig"}*F*).

Suppression of 8.3-CD8^+^ T-cell--enhanced diabetes by the B10 *Idd9.1* region requires endogenous T- but not B-cells.
----------------------------------------------------------------------------------------------------------------------

To ascertain whether the CD8^+^ T-cell--extrinsic effects of B10 *Idd9.1* on 8.3-CD8^+^ T-cell cross-priming in vivo were associated with B10 *Idd9.1*\'s antidiabetogenic activity, we introduced a recombination activating gene (*Rag2*) deficiency into 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice. Although penetrance of type 1 diabetes in 8.3-NOD.*Rag2*^−/−^ mice is significantly lower than in 8.3-NOD mice (owing to lack of CD4^+^ T-cell help) ([@B15]), the incidence of diabetes in 8.3-NOD.*Rag2*^−/−^ and 8.3-NOD.B10 *Idd9.1*/*Rag2*^−/−^ mice was essentially the same ([Fig. 4](#F4){ref-type="fig"}*A*), indicating that the RAG-2 deficiency had completely abrogated the antidiabetogenic effects of the B10 *Idd9.1* allele. Because these mice export only 8.3-CD8^+^ T-cells (but not CD4^+^ T-cells or B-cells) to the peripheral lymphoid organs ([@B15]), we reasoned that the protective activity of B10 *Idd9.1* was mediated by endogenous T-cells and/or B-cells. To distinguish between these two possibilities, we introduced an immunoglobulin μ heavy chain gene (*Ig*μ) deficiency into 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice and followed both types of B-cell--deficient mice for development of diabetes. B-cell--deficient 8.3-NOD.*Ig*μ^−/−^ mice developed diabetes essentially like B-cell--competent 8.3-NOD mice, indicating that type 1 diabetes development in the 8.3-NOD model, unlike the case in nontransgenic NOD mice, is B-cell independent ([Fig. 4](#F4){ref-type="fig"}*B*). In contrast, 8.3-NOD.B10 *Idd9.1/Ig*μ^−/−^ mice remained protected from type 1 diabetes despite lacking B-cells, indicating that the protective effects of the B10 *Idd9.1* region are B-cell independent and mediated by endogenous T-cells.

![The antidiabetogenic effects of B10 *Idd9.1* are effector T-cell extrinsic and mediated by endogenous T-cells in a B-cell--independent manner. *A*: Incidence of diabetes in female 8.3-NOD.*Rag2*^−/−^ (*n* = 106) and 8.3-NOD.B10 *Idd9.1/Rag2*^−/−^ mice (*n* = 19). *B*: Incidence of diabetes in female 8.3-NOD.*Ig*μ^−/−^ (*n* = 33) and 8.3-NOD.B10 *Idd9.1/Ig*μ^−/−^ mice (*n* = 47). The Kaplan-Meier survival curves were compared with log-rank test.](zdb0011059570004){#F4}

The B10 *Idd9.1* region enhances the development and function of FoxP3^+^CD4^+^CD25^+^ regulatory T-cells.
----------------------------------------------------------------------------------------------------------

Prompted by these findings and the observation that the protective effect of the B10 *Idd9.1* interval of line 1565 was not associated with increased development of thymic iNKT cells ([@B9]) (supplementary Fig. 2), we investigated whether B10 *Idd9.1* might enhance the development and/or function of FoxP3^+^CD4^+^CD25^+^ regulatory T-cells (Tregs). We compared the relative size of the FoxP3^+^CD4^+^ T-cell subset in thymuses, spleens, MLNs, and PLNs of 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice. The lymphoid organs of 8.3-NOD.B10 *Idd9.1* mice contained higher percentages (albeit not absolute numbers) of FoxP3^+^CD4^+^ T-cells than those of 8.3-NOD mice, although the differences were relatively small and statistically significant only for thymuses and MLNs ([Fig. 5](#F5){ref-type="fig"}*A* and *B*, and supplementary Fig. 3*A*). These differences were not a peculiarity of TCR-transgenic mice, because the thymuses and MLNs of nontransgenic NOD.B10 *Idd9.1* mice also contained significantly higher percentages of these T-cells compared with NOD mice ([Fig. 5](#F5){ref-type="fig"}*C*). As expected, there were no differences in the percentages of FoxP3^+^ T-cells within the CD4^+^CD25^+^ T-cell subsets ([Fig. 5](#F5){ref-type="fig"}*A* and *C*). These CD4^+^CD25^+^ T-cells had all the hallmarks of CD4^+^CD25^+^ Tregs described in other strains: they expressed GITR, FR4, CD134, and transforming growth factor β (TGF-β; [Fig. 5](#F5){ref-type="fig"}*D*), and produced IFN-γ, IL-4, and IL-10 when stimulated with plate-bound anti-CD3 mAb in the presence, but not absence, of rhIL-2 ([Fig. 5](#F5){ref-type="fig"}*E*). The CD4^+^CD25^+^ T-cells of transgenic and nontransgenic NOD and NOD.B10 *Idd9.1* mice expressed similar levels of all these markers, including CD25 and FoxP3 ([Fig. 5](#F5){ref-type="fig"}*F* and data not shown).

![Effects of B10 *Idd9.1* on the size and phenotype of the regulatory FoxP3^+^CD4^+^CD25^+^ Treg subset. *A*: Representative FoxP3/CD25 flow cytometry profiles. *B*: Percentages of FoxP3^+^ cells in the CD4^+^ and CD4^+^CD25^+^ T-cell subsets in the MLNs, PLNs, spleens (Spl), and thymuses (Thy) of 8- to 11-week-old 8.3-NOD (*n* = 12) and 8.3-NOD.B10 *Idd9.1* (*n* = 11) mice. Values correspond to the means ± standard errors. *P* values were calculated with Mann-Whitney *U* test. *C*: Percentages of FoxP3^+^ in the CD4^+^ and CD4^+^CD25^+^ T-cell subsets in the spleens, MLNs, PLNs, and thymuses of 8- to 11-week-old NOD (*n* = 9 for spleens, MLNs, and PLNs; *n* = 5 for thymuses) and NOD.B10 *Idd9.1* (*n* = 8 for spleens, MLNs, PLNs; *n* = 4 for thymuses) mice. *D*: GITR, FR4, CD134, and surface TGF-β flow cytometry profiles of CD4^+^CD25^+^ and CD4^+^CD25^−^ cells from NOD and NOD.B10 *Idd9.1* mice. Values correspond to the means ± standard errors of two to four experiments/strain type. *E*: Proliferation and cytokine production by CD4^+^CD25^+^ cells from NOD and NOD.B10 *Idd9.1* mice in response to plate-bound anti-CD3 mAb in the absence/presence of rhIL-2. Values correspond to the means ± standard errors of three independent experiments. *F*: Comparison of FoxP3 and CD25 mean fluorescence intensities for FoxP3^+^CD4^+^CD25^+^ T-cells from both types of mice.](zdb0011059570005){#F5}

We next asked whether these B10 *Idd9.1*-associated differences in the relative size of the FoxP3^+^CD4^+^CD25^+^ Treg subset were accompanied by differences in suppressive activity. We first compared the ability of CD4^+^CD25^+^ (and CD4^+^CD25^−^) T-cells purified from NOD.B10 *Idd9.1* and NOD mice to suppress the activation of naive 8.3-CD8^+^ T-cells from 8.3-NOD mice in response to NRP-A7 peptide--pulsed APCs. The CD4^+^CD25^+^ T-cells purified from 8.3-NOD.B10 *Idd9.1* or NOD.B10 *Idd9.1* mice had significantly higher regulatory activity than the CD4^+^CD25^+^ T-cells purified from 8.3-NOD or NOD mice, respectively, at different CD4^+^CD25^+^/CD8^+^ T-cell ratios ([Fig. 6](#F6){ref-type="fig"}*A* and *B*, and supplementary Fig. 3*B*). The CD4^+^CD25^−^ T-cells of both types of mice were not suppressive in these assays (data not shown), as described previously ([@B27]). These strain differences in Treg function were also true in vivo. Whereas 8.3-NOD.*Rag2*^−/−^ hosts transfused with CD4^+^CD25^+^ T-cells from wild-type NOD donors developed spontaneous diabetes essentially like nonmanipulated 8.3-NOD.*Rag2*^−/−^ mice ([@B15]), 8.3-NOD.*Rag2*^−/−^ hosts transfused with CD4^+^CD25^+^ T-cells from NOD.B10 *Idd9.1* mice remained diabetes free throughout the follow-up period ([Fig. 6](#F6){ref-type="fig"}*C*).

![Effects of B10 *Idd9.1* on the in vitro and in vivo suppressive activity of CD4^+^CD25^+^ regulatory T-cells. *A* and *B*: IFN-γ production by naive 8.3-CD8^+^ T-cells from 8.3-NOD mice in response to NRP-A7--pulsed APCs in the presence of CD4^+^CD25^+^ T-cells from 8.3-NOD and 8.3-NOD.B10 *Idd9.1* mice (*A*) or NOD and NOD.B10 *Idd9.1* mice (*B*), at different Treg/responder ratios. Graphs are representative of five (*A*) and three (*B*) independent experiments. *C*: Incidence of spontaneous diabetes in 8.3-NOD.*Rag2*^−/−^ hosts (*n* = 28) transfused with 2 × 10^5^ CD4^+^CD25^+^ T-cells from NOD (*n* = 16) or NOD.B10 *Idd9.1* donors (*n* = 12). *P* values for *A* and *B* were calculated with two-way ANOVA, and with log-rank for *C*.](zdb0011059570006){#F6}

Taken together, these data are consistent with the idea that diabetes resistance afforded by the B10 *Idd9.1* interval is mediated, at least in part, by enhanced development and function of CD4^+^CD25^+^ regulatory T-cells.

DISCUSSION
==========

Analyses of *Idd*-congenic NOD mice, in which type 1 diabetes--associated chromosomal regions are replaced by the corresponding regions found in nondiabetes-prone strains of mice, such as B6 and B10, have demonstrated the existence of more than 20 non--MHC-linked type 1 diabetes--associated regions/loci ([@B1],[@B28]). The nature of the genes that are responsible for these associations has been resolved for only a few *Idd* regions, including *Idd16-*β*2m* ([@B29]), *Idd3-Il2* ([@B14]), *Idd5.1-Ctla4* ([@B30],[@B31]), and *Idd5.2-Nramp1* ([@B30],[@B32],[@B33]). Furthermore, with the exception of *Idd3* ([@B14]), which controls Treg development and function, the mechanisms by which most of these loci contribute to the diabetogenic process remain unclear.

The current study aimed to elucidate mechanisms underlying the resistance to type 1 diabetes afforded by B10 *Idd9* ([@B5]), to help pave the way toward eventual identification of the responsible gene. We compared the fate and diabetogenicity of a type 1 diabetes--relevant autoreactive CD8^+^ T-cell population in B10 *Idd9*--congenic versus noncongenic TCR-transgenic NOD mice. We found that this reductionist system, which has enabled us to solve *Idd3* ([@B14]), is not informative to dissect mechanisms underlying *Idd9.2*- and *Idd9.3*-linked suppression, presumably because the large size of the transgenic CD8^+^ T-cell population born by these mice largely overwhelms the corresponding antidiabetogenic mechanisms. This, however, was not the case for *Idd9.1.* Our data show that *Idd9.1* regulates the suppressive activity and antidiabetogenic potential of FoxP3^+^CD4^+^CD25^+^ Tregs. Tregs arising in B10 *Idd9.1*--congenic NOD mice were significantly more suppressive and antidiabetogenic than those arising in NOD mice. Because FoxP3^+^CD4^+^ T-cells suppress diabetogenic T-cell responses, at least in part, by inhibiting DCs in the pancreatic draining lymph nodes ([@B27]), these observations are consistent with the suboptimal ability of autoantigen-loaded (in vivo) and peptide-pulsed (ex vivo) PLN DCs from NOD.B10 *Idd9.1* mice to support 8.3-CD8^+^ T-cell activation, both in vitro and in vivo; selective suppression of PLN DCs in these mice may result from cognate suppression of autoantigen-loaded DCs, which predominantly (if not exclusively) reside in the PLNs, by local autoregulatory CD4^+^CD25^+^ Tregs. Accordingly, we propose that B10 *Idd9.1*--"enhanced" Tregs contribute to B10 *Idd9.1*--linked type 1 diabetes inhibition by suppressing the activation of CD8^+^ (and possibly other) effector T-cells in the pancreatic draining lymph nodes, without affecting their developmental biology or intrinsic diabetogenic potential. These data might explain the observations of Chamberlain et al. in mice expressing a rat insulin promoter-driven tumor necrosis factor α transgene, in which B10 *Idd9.1* somehow suppressed the ability of CD8^+^ T-cells to respond to islet-infiltrating APCs ([@B34]). The results are also compatible with the DC phenotype described by O\'Keeffe et al. ([@B12]), with the caveat that this congenic strain, unlike the one described here, was produced using B6, as opposed to B10, donor mice and that B10 and B6 DNAs differ substantially in the distal region of chromosome 4 (supplementary Fig. 1). These observations, however, do not exclude, and are compatible with, possible effects of *Idd9.1* polymorphisms on other lymphocyte populations. For example, it has been reported that a B10 chromosome 4 region partially overlapping the B10 *Idd9.1* fragment studied here restores impaired iNKT cell development and an iNKT cell--related DC phenotype described in NOD mice ([@B9]). Our congenic line 1565, however, bears a B10 chromosome 4 fragment that overlaps only the distal 30% of the B10 chromosome 4 fragment present in Ueno et al.\'s R201 line. Furthermore, line 1565 does not display Ueno et al.\'s iNKT cell phenotype, suggesting that this phenotype is encoded in a gene that is not in the overlapping region. Also, our work does not exclude possible effects of genes within *Idd9.1*, *Idd9.2*, and/or *Idd9.3* on peripheral tolerance of autoreactive T-cell clones other than those expressing the 8.3-TCR ([@B35]), such as for example CD8^+^ T-cells recognizing IGRP~206--214~ with higher avidity ([@B36]).

It is intriguing that the effects of the B10 *Idd9.1* allele on Treg function and type 1 diabetes susceptibility observed in this study are remarkably similar to those we have described recently for B6 *Idd3*, where Treg development and function are enhanced by increased transcriptional activity of *Il2* ([@B14]). Accordingly, it is tempting to suspect that regulatory lymphocytes, including the FoxP3^+^CD4^+^CD25^+^ subset, may be common targets of type 1 diabetes--associated chromosomal regions. This hypothesis is compatible with what we know about the type 1 diabetes gene associations in humans. In addition to the *IL2-IL21* region on human chromosome 4q27 ([@B2],[@B4],[@B37]), and *IL2RA* on chromosome 10p15.1, which encodes CD25, the high-affinity receptor for IL-2 expressed by activated T-cells, and FoxP3^+^CD4^+^CD25^+^ Tregs ([@B37][@B38][@B39]--[@B40]), several other candidate human type 1 diabetes--associated loci play a role in Treg development and function. For example, the type 1 diabetes susceptibility gene *CTLA4* on chromosome 2q33.2 encodes a negative regulator of T-cell--mediated immunity ([@B31],[@B41],[@B42]). The susceptibility allele generates reduced levels of an alternatively spliced transcript that encodes the soluble form of CTLA-4, which has been correlated with variations in the peripheral frequency of CD4^+^CD25^+^ Tregs, which constitutively express CTLA-4 ([@B43]). *PTPN22* on chromosome 1p13.2, associated with susceptibility to a number of autoimmune diseases, including type 1 diabetes ([@B40], [@B44][@B45]--[@B46]), encodes lymphoid tyrosine-phosphatase (LYP), another negative regulator of T-cell activation. A nonsynonymous polymorphism (R620W) abolishes the binding of Csk, a negative regulatory kinase, to LYP. Consequently, the R620W LYP variant results in a gain of function that presumably enables LYP to more effectively suppress T-cell signaling compared with the non--type 1 diabetes--associated variants. It has been suggested that *PTPN22* polymorphisms contribute to autoimmune disease susceptibility by impairing negative selection of autoreactive thymocytes and by decreasing the number and function of CD4^+^CD25^+^ Tregs ([@B47],[@B48]). Another locus possibly implicated in autoimmune disease susceptibility by modulating T-cell signaling is *PTPN2* on chromosome 18p11.21, a nonreceptor type 2 tyrosine phosphatase that is a negative regulator of T-cell signaling ([@B2]).

The fine-mapping of *Idd9.1* has not progressed sufficiently to productively comment on candidate genes present in the region. The B10-derived congenic interval present in the *Idd9.1* strain used in this study (line 1565) has 329 annotated genes in this 18.5-Mb segment. The *Idd11* region as defined by B6-derived congenic strains ([@B16]) is an ∼8-Mb region that is wholly contained within the *Idd9.1* interval defined by the congenic strain used in this study. However, B6 and B10 are not identical by descent throughout the overlapping region (<http://phenome.jax.org>); from SNP analyses, B6 and B10 differ at 32.3% of the SNPs within the 8-Mb *Idd9.1*/*Idd11* interval (supplementary Fig. 1). Notably, within this 8 Mb, there are small regions that appear to be identical-by-descent for B6 and B10, including ∼200 kb surrounding *Lck*, a previously highlighted candidate gene in the *Idd9.1* region ([@B16]), where the ancestral haplotype shared by the B6 and B10 strains differs from that present in NOD mice (supplementary Fig. 1). Further fine-mapping and gene expression studies are required to define the genes that are responsible for *Idd9.1*- and *Idd11*-mediated type 1 diabetes protection and to determine whether the protective alleles are indeed shared by the B6 and B10 strains in this region.

In conclusion, we have shown that the B10 *Idd9.1* locus affords diabetes resistance, at least in part, by promoting the function of CD4^+^CD25^+^ regulatory T-cells without altering the developmental biology of effector CD8^+^ T-cells.

Supplementary Material
======================

###### Online-Only Appendix

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was supported by grants from the Canadian Institutes of Health Research (to P.S.). J.Y. was supported by fellowships from the Canadian Diabetes Association and the Juvenile Diabetes Research Foundation (JDRF). P.S. is a Scientist of the Alberta Heritage Foundation for Medical Research (AHFMR). The JMDRC is supported by the Diabetes Association (Foothills). L.S.W. is supported by grants from the JDRF and the Wellcome Trust (WT) and is a JDRF/WT Principal Research Fellow. Support for this work was also provided by National Institute of Allergy and Infectious Disease (NIAID) Grant AI 070351 from the National Institutes of Health. The Cambridge Institute for Medical Research (CIMR) is in receipt of a Wellcome Trust Strategic Award (079895). The availability of NOD congenic mice through the Taconic Farms Emerging Models Program has been supported by grants from the Merck Genome Research Institute, NIAID, and the JDRF.

No potential conflicts of interest relevant to this article were reported.

We thank S. Bou, S. Thiessen, M. Deuma-Myers, H. Metselaar, M. DeCrom, and T. Irvine for technical assistance with mouse breeding, genotyping, and animal care; L. Kennedy and L. Robertson for flow cytometry; C. Gwozd for histology; Y. Yang for aGalCer/Cd1 tetramers; and S. Tsai, A. Shameli, and Y. Yang for helpful discussions.
